Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa
β Scribed by Maiorano, Eugenio; Favia, Gianfranco; Maisonneuve, Patrick; Viale, Giuseppe
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 764 KB
- Volume
- 185
- Category
- Article
- ISSN
- 0022-3417
No coin nor oath required. For personal study only.
β¦ Synopsis
To evaluate the clinical significance of the expression of epidermal growth factor receptor (EGFr) in oral squamous cell carcinoma (SCC), 100 formalin-fixed, paraffin-embedded cases of this tumour and ten samples of normal oral mucosa were immunostained with a monoclonal anti-EGFr antibody using an immunoalkaline phosphatase (APAAP) technique. EGFr immunoreactivity was detected in 36 of 100 tumours and in all samples of normal mucosa. Tumour cells demonstrated distinct membrane staining in 14 cases and predominantly cytoplasmic staining in 22 additional cases. EGFr was exclusively localized on the cell membrane of normal epithelial cells. Kaplan-Meyer survival curves and Cox proportional hazard regression models were used to assess overall survival and disease-free survival. A significant positive correlation was shown between EGFr membranous immunoreactivity and prolonged survival, in both univariate and multivariate analyses. Accordingly, patients with oral SCC showing down-regulated expression of membranous EGFr, who are more likely to suffer recurrence and death, should be strictly followed up and possibly treated with more aggressive therapeutic regimens. 1998 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract ## Background Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the lack of correlation between EGFR expression in the HNSCC tumor and clinical responses to EGFR
Zhang et al. recently reported an activating mutation of the receptor tyrosine kinase fibroblast growth factor receptor 3 in 62% of 71 oral squamous cell carcinomas (OSCC). 1 More than 300,000 new cases of OSCC are diagnosed annually, worldwide. This aggressive epithelial cancer is associated with s